Can Bonerge’s EquoYouth S-equol study strengthen evidence for menopause relief?
Bonerge Lifescience begins an EquoYouth S-equol menopause study as researchers test whether new data can strengthen a contested supplement case.
Pharma & Biotech
Pharma & Biotech
Is Noema Pharma AG building a multi-symptom menopause therapy platform with cendifensine?
Is Noema Pharma AG building a menopause therapy platform? Discover how cendifensine could reshape non-hormonal treatment strategies
Pharma & Biotech
Can Vistagen turn refisolone into a fast-acting alternative for menopausal hot flashes?
Vistagen advances refisolone for menopausal hot flashes after FDA clearance. Find out what this means for non-hormonal treatment options.
Pharma & Biotech
What AbCellera’s upcoming ABCL635 Phase 1 data could reveal about the future of menopause treatment
AbCellera will reveal Phase 1 ABCL635 data on May 11. Read why this menopause drug update could matter for investors and women’s health watchers.
Pharma & Biotech
Why Pendulum Therapeutics is taking its microbiome platform beyond metabolic health with Mayo Clinic
Pendulum Therapeutics has expanded its Mayo Clinic collaboration into women’s health and dermatology. Read what this could mean for microbiome medicine.
Pharma & Biotech
Galderma backs new evidence for Sculptra and Restylane in fast-evolving patient demand segments
Read how Galderma’s new interim data could influence aesthetic treatment planning in menopause and GLP-1-related volume loss.
Medical Devices & Diagnostics
Can Peri turn perimenopause tracking into a credible new women’s health device category?
Peri has launched a perimenopause wearable, but can symptom tracking become clinical-grade insight? Read the deeper industry analysis now.
Pharma & Biotech
Can ABCL635 redefine non-hormonal menopause treatment? Inside AbCellera’s Phase 2 push
AbCellera advances ABCL635 into Phase 2 for hot flashes. Find out what this means for non-hormonal menopause care and the biotech’s GPCR strategy.